title: Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications.
abstract: Obesity, particularly abdominal obesity, is currently considered a chronic low-grade inflammatory condition that plays an active role in the development of the pathophysiologic phenomena responsible for metabolic syndrome and cardiovascular disease through the secretion of proinflammatory adipokines and cytokines. In recent years clear genetic, pathogenic, and epidemiologic links have been established between psoriasis and obesity, with important implications for health. The relationship between the 2 conditions is probably bidirectional, with obesity predisposing to psoriasis and psoriasis favoring obesity. Obesity also has important implications in the treatment of psoriasis, such as a greater risk of adverse effects with conventional systemic drugs and reduced efficacy and/or increased cost with biologic agents, for which dosage should be adjusted to the patient's weight.
authors.affiliation: Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España. Electronic address: jmcarrascosac@hotmail.com.
authors.forename: J M
authors.initials: JM
authors.lastname: Carrascosa
authors.affiliation: Servicio de Dermatología, Hospital de Manacor, Manacor, Mallorca, España.
authors.forename: V
authors.initials: V
authors.lastname: Rocamora
authors.affiliation: Complejo Hospitalario Universitario de La Coruña, La Coruña, España.
authors.forename: R M
authors.initials: RM
authors.lastname: Fernandez-Torres
authors.affiliation: Servicio de Dermatología, Hospital Universitario Reina Sofía, Madrid, España.
authors.forename: R
authors.initials: R
authors.lastname: Jimenez-Puya
authors.affiliation: Servicio de Dermatología, Hospital Universitario Reina Sofía, Madrid, España.
authors.forename: J C
authors.initials: JC
authors.lastname: Moreno
authors.affiliation: Servicio de Dermatología, Hospital de Manacor, Manacor, Mallorca, España.
authors.forename: N
authors.initials: N
authors.lastname: Coll-Puigserver
authors.affiliation: Complejo Hospitalario Universitario de La Coruña, La Coruña, España.
authors.forename: E
authors.initials: E
authors.lastname: Fonseca
mesh_terms: D017667:Adipocytes / Q000378:metabolism / Q000473:pathology; D054392:Adipokines / Q000378:metabolism / Q000502:physiology; D000273:Adipose Tissue / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000503:physiopathology; D015984:Causality; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002450:Cell Communication; D016207:Cytokines / Q000378:metabolism / Q000502:physiology; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006728:Hormones / Q000502:physiology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008214:Lymphocytes / Q000473:pathology; D024821:Metabolic Syndrome / Q000209:etiology / Q000503:physiopathology; D008954:Models, Biological; D009765:Obesity / Q000150:complications / Q000276:immunology* / Q000503:physiopathology; D011701:PUVA Therapy; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy / Q000276:immunology*
chemical_list: D054392:Adipokines; D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D015815:Cell Adhesion Molecules; D016207:Cytokines; D005230:Fatty Acids, Nonesterified; D006728:Hormones; D007155:Immunologic Factors